Cracking the Genomic Code of CDK4/6 Inhibitor Resistance.
Seth A WanderAditya BardiaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
The therapeutic approach to metastatic hormone-receptor positive, human epidermal growth factor-2 negative metastatic breast cancer (HR+/HER2- MBC) has evolved rapidly over recent years. The cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have become first-line targeted agents of choice, in combination with an anti-estrogen. Simultaneously, the clinical landscape of therapeutic options has been rapidly shifting, with novel anti-estrogens, signal transduction inhibitors, and next-generation CDK inhibitors in various staging of development. Given these dynamic changes, understanding the genomic and molecular landscape of resistance to currently available anti-estrogen therapy and CDK4/6 inhibitors represents a major focus of translational breast cancer research globally.
Keyphrases
- cell cycle
- growth factor
- metastatic breast cancer
- cell proliferation
- endothelial cells
- squamous cell carcinoma
- copy number
- estrogen receptor
- small cell lung cancer
- single cell
- lymph node
- cancer therapy
- stem cells
- cell death
- dna methylation
- induced pluripotent stem cells
- decision making
- single molecule
- drug delivery
- mesenchymal stem cells
- cell therapy